PharmAust Limited PAA.AX · Stock Open PharmAust Limited in new tab
PharmAust Limited Analysis (PAA.AX)
Is PharmAust Limited a good investment? PharmAust Limited (PAA.AX) is currently trading at 0.2300 AUD.
Investor FAQ
Does PharmAust Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is PharmAust Limited?
PharmAust Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 20, 2019 | 1.100000 |
| Nov. 10, 2016 | 1.040000 |
| Oct. 30, 2015 | 0.050000 |
| Nov. 15, 2004 | 0.200000 |
Community Discussion